HomeCompareGNTLF vs DIVO

GNTLF vs DIVO: Dividend Comparison 2026

GNTLF yields 200.00% · DIVO yields 6.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GNTLF wins by $119.33M in total portfolio value
10 years
GNTLF
GNTLF
● Live price
200.00%
Share price
$1.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$119.36M
Annual income
$60,176,096.29
Full GNTLF calculator →
DIVO
DIVO
● Live price
6.49%
Share price
$44.85
Annual div
$2.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$981.68
Full DIVO calculator →

Portfolio growth — GNTLF vs DIVO

📍 GNTLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGNTLFDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GNTLF + DIVO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GNTLF pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GNTLF
Annual income on $10K today (after 15% tax)
$17,000.00/yr
After 10yr DRIP, annual income (after tax)
$51,149,681.85/yr
DIVO
Annual income on $10K today (after 15% tax)
$552.00/yr
After 10yr DRIP, annual income (after tax)
$834.43/yr
At 15% tax rate, GNTLF beats the other by $51,148,847.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GNTLF + DIVO for your $10,000?

GNTLF: 50%DIVO: 50%
100% DIVO50/50100% GNTLF
Portfolio after 10yr
$59.70M
Annual income
$30,088,538.98/yr
Blended yield
50.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on DIVO right now

GNTLF
Analyst Ratings
1
Sell
Consensus: Sell
Altman Z
135.3
Piotroski
3/9
DIVO
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GNTLF buys
0
DIVO buys
0
No recent congressional trades found for GNTLF or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGNTLFDIVO
Forward yield200.00%6.49%
Annual dividend / share$2.00$2.91
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$119.36M$30.7K
Annual income after 10y$60,176,096.29$981.68
Total dividends collected$112.49M$8.2K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: GNTLF vs DIVO ($10,000, DRIP)

YearGNTLF PortfolioGNTLF Income/yrDIVO PortfolioDIVO Income/yrGap
1← crossover$30,700$20,000.00$11,349$649.42+$19.4KGNTLF
2$90,232$57,383.18$12,833$688.83+$77.4KGNTLF
3$254,173$157,624.56$14,459$727.90+$239.7KGNTLF
4$686,927$414,961.74$16,238$766.49+$670.7KGNTLF
5$1,783,118$1,048,106.39$18,179$804.47+$1.76MGNTLF
6$4,450,613$2,542,677.12$20,293$841.71+$4.43MGNTLF
7$10,693,420$5,931,263.38$22,591$878.14+$10.67MGNTLF
8$24,760,608$13,318,648.86$25,087$913.65+$24.74MGNTLF
9$55,315,649$28,821,798.66$27,791$948.18+$55.29MGNTLF
10$119,363,841$60,176,096.29$30,718$981.68+$119.33MGNTLF

GNTLF vs DIVO: Complete Analysis 2026

GNTLFStock

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Full GNTLF Calculator →

DIVOETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →
📬

Get this GNTLF vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GNTLF vs SCHDGNTLF vs JEPIGNTLF vs OGNTLF vs KOGNTLF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.